Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
TNGX Stock Forecast 2026-2027
$27.77
Current Price
$4.01B
Market Cap
Buy 11
Hold 1
Sell 0
Wall St Analyst Ratings
Distance to TNGX Price Targets
+8.0%
To High Target of $30.00
-26.2%
To Median Target of $20.50
-42.4%
To Low Target of $16.00
TNGX Price Momentum
+9.6%
1 Week Change
+43.0%
1 Month Change
+1,763.8%
1 Year Change
+213.4%
Year-to-Date Change
-2.3%
From 52W High of $28.41
+2,596.1%
From 52W Low of $1.03
📊 TOP ANALYST CALLS
Did TNGX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Tango Therapeutics is one of their latest high-conviction picks.
Latest TNGX Stock Price Targets & Analyst Predictions
Based on our analysis of 15 Wall Street analysts, TNGX has a bullish consensus with a median price target of $20.50 (ranging from $16.00 to $30.00). The overall analyst rating is Strong Buy (9.5/10). Currently trading at $27.77, the median forecast implies a -26.2% downside. This outlook is supported by 11 Buy, 1 Hold, and 0 Sell ratings.
The most optimistic forecast comes from John Newman at Canaccord Genuity, projecting a 8.0% upside. Conversely, the most conservative target is provided by Yuan Zhi at B. Riley Securities, suggesting a 42.4% downside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
TNGX Analyst Ratings
11
Buy
1
Hold
0
Sell
TNGX Price Target Range
Low
$16.00
Average
$20.50
High
$30.00
Current: $27.77
Latest TNGX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for TNGX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Apr 2, 2026 | Canaccord Genuity | John Newman | Buy | Initiates | $30.00 |
| Mar 11, 2026 | Mizuho | Joseph Catanzaro | Outperform | Maintains | $20.00 |
| Mar 9, 2026 | Stifel | Laura Prendergast | Buy | Maintains | $24.00 |
| Mar 6, 2026 | Guggenheim | Michael Schmidt | Buy | Maintains | $20.00 |
| Mar 6, 2026 | HC Wainwright & Co. | Robert Burns | Buy | Maintains | $27.00 |
| Mar 6, 2026 | Wedbush | Robert Driscoll | Outperform | Maintains | $19.00 |
| Feb 23, 2026 | Mizuho | Joseph Catanzaro | Outperform | Initiates | $19.00 |
| Feb 6, 2026 | Guggenheim | Michael Schmidt | Buy | Maintains | $18.00 |
| Jan 16, 2026 | Piper Sandler | Kelsey Goodwin | Overweight | Maintains | $14.00 |
| Dec 4, 2025 | Stifel | Laura Prendergast | Buy | Initiates | $15.00 |
| Nov 18, 2025 | B. Riley Securities | Yuan Zhi | Buy | Maintains | $14.00 |
| Nov 18, 2025 | Wolfe Research | Kalpit Patel | Peer Perform | Initiates | $N/A |
| Oct 24, 2025 | Guggenheim | Charles Zhu | Buy | Maintains | $12.00 |
| Aug 19, 2025 | Piper Sandler | Kelsey Goodwin | Overweight | Initiates | $11.00 |
| Aug 6, 2025 | Guggenheim | Michael Schmidt | Buy | Maintains | $10.00 |
| Apr 14, 2025 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $13.00 |
| Dec 5, 2024 | Cantor Fitzgerald | Eric Schmidt | Overweight | Reiterates | $N/A |
| Nov 11, 2024 | B. Riley Securities | Yuan Zhi | Buy | Maintains | $8.00 |
| Nov 8, 2024 | HC Wainwright & Co. | Robert Burns | Buy | Reiterates | $13.00 |
| Nov 7, 2024 | Guggenheim | Charles Zhu | Buy | Maintains | $8.00 |
Tango Therapeutics Inc. (TNGX) Competitors
The following stocks are similar to Tango Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
TNGX
Tango Therapeutics
mkt cap
3.80B
Tango Therapeutics Inc. (TNGX) Financial Data
Valuation Metrics
Market Cap
$4.01B
Enterprise Value
$3.49B
P/E Ratio
N/A
PEG Ratio
-16.5x
Price/Sales
61.0x
Growth & Margins
Revenue Growth (YoY)
-100.0%
Gross Margin
N/A
Operating Margin
-178.4%
Net Margin
-162.9%
EPS Growth
-100.0%
Financial Health
Cash/Price Ratio
+8.7%
Current Ratio
16.3x
Debt/Equity
9.7x
ROE
-37.2%
ROA
-19.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Tango Therapeutics Inc. (TNGX) Business Model
About Tango Therapeutics Inc.
What They Do
Develops novel cancer medicines targeting genetic vulnerabilities.
Business Model
Tango Therapeutics operates as a clinical-stage company, focusing on precision oncology by discovering and developing targeted therapies for cancer patients with specific genetic mutations. The company generates revenue through strategic collaborations with pharmaceutical partners and potentially through the commercialization of its investigational therapies as they progress through clinical trials.
Additional Information
Founded in 2017 and based in Boston, Massachusetts, Tango Therapeutics utilizes the principle of synthetic lethality to create therapies for cancers with defined genetic vulnerabilities. Its pipeline includes promising candidates in clinical trials aimed at treating pancreatic, lung, and glioblastoma cancers, addressing significant unmet medical needs in oncology.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
137
CEO
Dr. Malte Peters M.D.
Country
United States
IPO Year
2020
Website
www.tangotx.comTango Therapeutics Inc. (TNGX) Latest News & Analysis
Latest News
Quick Summary
Matthew Gall has been appointed Chief Financial Officer, with additional key hires enhancing expertise in clinical operations, corporate strategy, and project leadership.
Why It Matters
Matthew Gall's appointment as CFO signals potential financial stability and strategic direction, while additional key hires enhance operational efficiency, boosting investor confidence in future growth.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
On April 1, 2026, 27,000 shares were sold via option exercise for $572,000, reducing Adam's holdings by 19.34% from 139,622 to 112,622 shares.
Why It Matters
The significant reduction in Adam's common stock position and the cash generated from the option exercise could signal confidence or strategic shifts, impacting stock valuation and investor sentiment.
Source: The Motley Fool
Market Sentiment:
Neutral
Quick Summary
Adam Crystal sold 20,251 shares on March 5, 2026, for approximately $304,000, reducing his holdings from 132,873 to 112,622 shares, a decrease of 15.24%.
Why It Matters
Adam Crystal's significant sale of shares may signal a lack of confidence in the company's future performance, potentially impacting investor sentiment and stock price.
Source: The Motley Fool
Market Sentiment:
Neutral
X4 Pharmaceuticals, Immuneering and Tango Therapeutics Are Getting New Analyst Attention
1 month ago
Quick Summary
Analysts have become more positive on three small-cap biotechs, initiating coverage and maintaining Buy ratings ahead of key clinical events expected in 2026.
Why It Matters
Positive analyst sentiment and Buy ratings for small-cap biotechs indicate potential growth opportunities, especially with upcoming clinical catalysts that could drive stock performance.
Source: 24/7 Wall Street
Market Sentiment:
Positive
Quick Summary
Tango Therapeutics' stock reached a record high following a clinical collaboration with Erasca to test the ERAS-0015/vopimetostat combination in MTAP-deleted RAS-mutant cancers.
Why It Matters
Tango Therapeutics' record-high stock reflects strong market confidence following a significant collaboration, potentially enhancing its growth and innovation in cancer treatments.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
Tango Therapeutics is downgraded to Hold post-rally. Key trial for Vopimetostat in pancreatic cancer underway. Strong cash position ($343M) and partnerships noted, but competition is intense.
Why It Matters
The downgrade to Hold reflects caution after a rally, signaling potential volatility. Key trials and partnerships indicate growth potential, but competition may impact future performance.
Source: Seeking Alpha
Market Sentiment:
Positive
Frequently Asked Questions About TNGX Stock
What is Tango Therapeutics Inc.'s (TNGX) stock forecast for 2026?
Based on our analysis of 15 Wall Street analysts, Tango Therapeutics Inc. (TNGX) has a median price target of $20.50. The highest price target is $30.00 and the lowest is $16.00.
Is TNGX stock a good investment in 2026?
According to current analyst ratings, TNGX has 11 Buy ratings, 1 Hold ratings, and 0 Sell ratings. The stock is currently trading at $27.77. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for TNGX stock?
Wall Street analysts predict TNGX stock could reach $20.50 in the next 12 months. This represents a -26.2% decrease from the current price of $27.77. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Tango Therapeutics Inc.'s business model?
Tango Therapeutics operates as a clinical-stage company, focusing on precision oncology by discovering and developing targeted therapies for cancer patients with specific genetic mutations. The company generates revenue through strategic collaborations with pharmaceutical partners and potentially through the commercialization of its investigational therapies as they progress through clinical trials.
What is the highest forecasted price for TNGX Tango Therapeutics Inc.?
The highest price target for TNGX is $30.00 from John Newman at Canaccord Genuity, which represents a 8.0% increase from the current price of $27.77.
What is the lowest forecasted price for TNGX Tango Therapeutics Inc.?
The lowest price target for TNGX is $16.00 from Yuan Zhi at B. Riley Securities, which represents a -42.4% decrease from the current price of $27.77.
What is the overall TNGX consensus from analysts for Tango Therapeutics Inc.?
The overall analyst consensus for TNGX is bullish. Out of 15 Wall Street analysts, 11 rate it as Buy, 1 as Hold, and 0 as Sell, with a median price target of $20.50.
How accurate are TNGX stock price projections?
Stock price projections, including those for Tango Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: April 22, 2026 3:57 AM UTC